Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Outperform” Rating from Wedbush
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued on Friday,RTT News reports. They currently have a $23.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 233.82% from the stock’s previous close. A number of other equities […]
More Stories
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...
Desire 2026: Release Date, Cast Members, Trailer, Audio, and More
Netflix is expanding its international movie lineup with intense action, thriller, and drama that explore the complexities of human emotions....
AI Assistants Overwhelmingly Cite Third-Party Lists, Not Company Homepages, Study Finds
Artificial intelligence assistants overwhelmingly cite third-party “best-of” and comparison pages rather than companies’ own websites, according to a new study...